Literature DB >> 27094946

The role of MRI in the evaluation of spondyloarthritis: a clinician's guide.

Walter P Maksymowych1.   

Abstract

Plain radiography remains the benchmark for diagnostic evaluation of spondyloarthritis although MRI has much great sensitivity because it can detect a variety of inflammatory lesions as well as fat metaplasia. So, it is the imaging modality of choice when pelvic radiographs are equivocal and especially when important treatment decisions have to be made. Appropriate imaging includes the use of T1-weighted and short tau inversion recovery sequences of the sacroiliac joint in the tilted coronal plane. If there is localized spinal symptomatology, sagittal scans of the spine may also be helpful. However, routine spinal imaging is not recommended. Current consensus designates a positive MRI for classification purposes as requiring the presence of two definite subchondral inflammatory lesions on a single coronal slice or the presence of one such lesion on two consecutive coronal slices. However, such inflammatory lesions can occur in healthy individuals and in those with nonspecific back pain. Erosions are more specific, and their presence can enhance confidence in the diagnosis. MRI, together with CRP, can be helpful in selecting which patients without radiographic sacroiliitis are most likely to respond to tumor necrosis factor inhibitor therapy. The role of MRI in monitoring of patients with SpA remains unclear although it may be helpful in excluding other sources of back pain. A major unanswered question is whether MRI may be useful in predicting relapse following withdrawal of TNFi in patients who have achieved sustained remission.

Entities:  

Keywords:  MRI; Short tau inversion recovery (STIR); Spondyloarthritis

Mesh:

Year:  2016        PMID: 27094946     DOI: 10.1007/s10067-016-3265-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  42 in total

1.  Metric Properties of the SPARCC Score of the Sacroiliac Joints - Data from Baseline, 3-month, and 12-month Followup in the SPACE Cohort.

Authors:  Rosaline van den Berg; Manouk de Hooge; Pauline A C Bakker; Floris van Gaalen; Victoria Navarro-Compán; Karen Minde Fagerli; Robert Landewé; Maikel van Oosterhout; Roberta Ramonda; Monique Reijnierse; Désirée van der Heijde
Journal:  J Rheumatol       Date:  2015-05-01       Impact factor: 4.666

2.  Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study.

Authors:  Jürgen Braun; Robert Landewé; Kay-Geert A Hermann; John Han; Songkai Yan; Paul Williamson; Désirée van der Heijde
Journal:  Arthritis Rheum       Date:  2006-05

3.  The radiographic diagnosis of sacroiliitis. A comparison of different views with computed tomograms of the sacroiliac joint.

Authors:  L M Ryan; G F Carrera; R W Lightfoot; R G Hoffman; F Kozin
Journal:  Arthritis Rheum       Date:  1983-06

4.  Fat metaplasia and backfill are key intermediaries in the development of sacroiliac joint ankylosis in patients with ankylosing spondylitis.

Authors:  Walter P Maksymowych; Stephanie Wichuk; Praveena Chiowchanwisawakit; Robert G Lambert; Susanne J Pedersen
Journal:  Arthritis Rheumatol       Date:  2014-11       Impact factor: 10.995

5.  Very early spondyloarthritis: where the inflammation in the sacroiliac joints starts.

Authors:  M Bollow; K-G A Hermann; T Biedermann; J Sieper; M Schöntube; J Braun
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

6.  MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib.

Authors:  S J Jarrett; F Sivera; L S Cawkwell; H Marzo-Ortega; D McGonagle; E Hensor; L Coates; P J O'Connor; A Fraser; P G Conaghan; P Emery
Journal:  Ann Rheum Dis       Date:  2008-10-24       Impact factor: 19.103

7.  Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.

Authors:  Martin Rudwaleit; Pascal Claudepierre; Paul Wordsworth; Eduardo Loza Cortina; Joachim Sieper; Martina Kron; Roberto Carcereri-De-Prati; Hartmut Kupper; Sonja Kary
Journal:  J Rheumatol       Date:  2009-02-27       Impact factor: 4.666

8.  MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.

Authors:  Pedro Machado; Robert B M Landewé; Jürgen Braun; Xenofon Baraliakos; Kay-Geert A Hermann; Benjamin Hsu; Daniel Baker; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2012-08-21       Impact factor: 19.103

9.  Validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging spinal inflammation index: is it necessary to score the entire spine?

Authors:  Walter P Maksymowych; Suhkvinder S Dhillon; Roy Park; David Salonen; Robert D Inman; Robert G W Lambert
Journal:  Arthritis Rheum       Date:  2007-04-15

10.  Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Robert G W Lambert; David Salonen; Proton Rahman; Robert D Inman; Robert L Wong; Steven G Einstein; Glen T D Thomson; Andre Beaulieu; Denis Choquette; Walter P Maksymowych
Journal:  Arthritis Rheum       Date:  2007-12
View more
  2 in total

1.  Magnetic resonance imaging in diffuse idiopathic skeletal hyperostosis: similarities to axial spondyloarthritis.

Authors:  Uri Arad; Ori Elkayam; Iris Eshed
Journal:  Clin Rheumatol       Date:  2017-03-31       Impact factor: 2.980

2.  Bone edema of the whole vertebral body: an unusual case of spondyloarthritis.

Authors:  Augusta Ortolan; Paolo Lazzarin; Mariagrazia Lorenzin; Lucia Rampin; Roberta Ramonda
Journal:  Clin Rheumatol       Date:  2016-09-27       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.